Tumour Killing Assays
Understanding whether a test biologic or small molecule can enhance tumour cell killing could well be a key component of your drug discovery program.
To assist, Aquila offers cell-mediated cytotoxicity (CMC) and antibody-dependent cytotoxic (ADCC) assays, using traditional label-release, to help you assess immune cell driven apoptosis of cultured tumour cells.
Our ADCC assays can be adapted to a range of tumour types and immune cell populations, such as T cells, NK cells, macrophages and neutrophils. They can also incorporate anti-TAA antibodies.
Please get in touch to learn more about our T Cell Killing Assays.